Palisade Bio (PALI) Cash & Equivalents (2010 - 2026)

Palisade Bio (PALI) has 17 years of Cash & Equivalents data on file, last reported at $132.6 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 1734.41% year-over-year to $132.6 million in Q1 2026; TTM through Mar 2026 was $132.6 million, a 1734.41% increase from a year earlier, with the FY2025 full-year figure at $132.4 million, up 1256.13% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $132.6 million, roughly flat from $132.4 million in the prior quarter.
• Over the last five years, Cash & Equivalents for PALI reached as high as $132.6 million in Q1 2026 and fell as low as $5.0 million in Q2 2022.
• Historically, Cash & Equivalents has averaged $24.6 million across 5 years, with a median of $11.4 million in 2024.
• Across the five-year window, Cash & Equivalents plunged 60.64% in 2022 and soared 1734.41% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $12.4 million in 2022, then grew by 0.4% to $12.4 million in 2023, then fell by 21.47% to $9.8 million in 2024, then jumped by 1256.13% to $132.4 million in 2025, then increased by 0.17% to $132.6 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $132.6 million in Q1 2026, $132.4 million in Q4 2025, and $5.2 million in Q3 2025.